Oncolys BioPharma Inc. (4588.T)
JPY 602.0
(-1.79%)
JPY 602.0
(-1.79%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 63.03 Million | 976.18 Million | 642.49 Million | 314.17 Million | 1.3 Billion | 168.54 Million |
| Cost of Revenue | 32.43 Million | 637.69 Million | 443.69 Million | 78.06 Million | 112.9 Million | 121.33 Million |
| Gross Profit | 30.6 Million | 338.48 Million | 198.8 Million | 236.11 Million | 1.19 Billion | 47.21 Million |
| Operating Expenses | 1.96 Billion | 1.54 Billion | 1.65 Billion | 1.91 Billion | 1.7 Billion | 1.29 Billion |
| Selling, General and Administrative Expenses | - | 574.64 Million | 725.93 Million | 877.98 Million | 1.07 Billion | 625.4 Million |
| Research and Development Expenses | 1.35 Billion | 947.49 Million | 825.47 Million | 987.24 Million | 562.69 Million | 605.82 Million |
| Other Expenses | 608.65 Million | 1.54 Billion | 1.65 Billion | 1.91 Billion | 1.7 Billion | 30 Thousand |
| Cost and Expenses | 1.99 Billion | 2.18 Billion | 2.09 Billion | 1.98 Billion | 1.81 Billion | 1.41 Billion |
| Operating Income | -1.92 Billion | -1.2 Billion | -1.45 Billion | -1.67 Billion | -511.46 Million | -1.24 Billion |
| Interest Expense | 3.6 Million | 3.94 Million | 4.16 Million | 4.17 Million | 3.94 Million | 2.79 Million |
| Income Tax Expense | 2.92 Million | 2.93 Million | 3.72 Million | 3.72 Million | 3.75 Million | 3.74 Million |
| Earnings before Tax | -1.93 Billion | -1.14 Billion | -1.61 Billion | -2.09 Billion | -908.59 Million | -1.23 Billion |
| Net Income | -1.93 Billion | -1.14 Billion | -1.61 Billion | -2.09 Billion | -912.34 Million | -1.23 Billion |
| Earnings Per Share Basic | -108.92 | -66.31 | -95.50 | -145.58 | -65.55 | -104.55 |
| Earnings Per Share Diluted | -108.92 | -66.31 | -95.50 | -145.58 | -65.55 | -104.55 |
| Weighted Average Shares Outstanding | 17.79 Million | 17.32 Million | 16.91 Million | 14.39 Million | 13.91 Million | 11.8 Million |
| Weighted Average Shares Outstanding (Diluted) | 17.79 Million | 17.32 Million | 16.91 Million | 14.39 Million | 13.91 Million | 11.8 Million |
| Gross Margin | 0.49 | 0.35 | 0.31 | 0.75 | 0.91 | 0.28 |
| EBIT Margin | -30.61 | -1.19 | -2.32 | -5.46 | -0.41 | -7.27 |
| Profit Margin | -30.75 | -1.18 | -2.51 | -6.67 | -0.70 | -7.32 |
| EBITDA | -1.92 Billion | -1.14 Billion | -1.6 Billion | -2.08 Billion | -901.53 Million | -1.22 Billion |
| Earnings Before Tax Margin | -30.62 | -1.23 | -2.26 | -5.33 | -0.39 | -7.40 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 31.38 Million | - | - | 63.03 Million | - | 28.03 Million |
| Cost of Revenue | - | - | 1.6 Million | 32.43 Million | 539 Thousand | 141 Thousand |
| Gross Profit | 31.38 Million | - | -1.6 Million | 30.6 Million | -539 Thousand | 27.89 Million |
| Operating Expenses | 445.88 Million | 378.87 Million | 617.34 Million | 1.96 Billion | 410.04 Million | 603.44 Million |
| Selling, General and Administrative Expenses | 144.05 Million | 156.73 Million | 162.73 Million | - | 149.12 Million | 145.51 Million |
| Research and Development Expenses | 301.83 Million | 222.14 Million | 454.6 Million | - | 260.38 Million | 457.79 Million |
| Other Expenses | -144.05 Million | - | - | -25.55 Million | 2.75 Million | - |
| Cost and Expenses | 445.88 Million | 378.87 Million | 618.94 Million | 1.99 Billion | 410.04 Million | 603.44 Million |
| Operating Income | -414.49 Million | -378.87 Million | -618.94 Million | -1.92 Billion | -410.04 Million | -575.41 Million |
| Interest Expense | 1.04 Million | 1.14 Million | 823 Thousand | 3.6 Million | 998 Thousand | 926 Thousand |
| Income Tax Expense | 931 Thousand | 940 Thousand | 733 Thousand | 2.92 Million | 736 Thousand | 721 Thousand |
| Earnings before Tax | -389.7 Million | -363.29 Million | -664.92 Million | -1.93 Billion | -403.34 Million | -544.35 Million |
| Net Income | -390.63 Million | -364.23 Million | -665.66 Million | -1.93 Billion | -404.08 Million | -545.07 Million |
| Earnings Per Share Basic | -18.73 | -18.24 | -35.09 | - | -23.02 | -31.47 |
| Earnings Per Share Diluted | -18.73 | -18.24 | -35.09 | - | -23.02 | -31.47 |
| Weighted Average Shares Outstanding | 20.85 Million | 19.97 Million | 18.97 Million | 17.79 Million | 17.55 Million | 17.32 Million |
| Weighted Average Shares Outstanding (Diluted) | 20.85 Million | 19.97 Million | 18.97 Million | 17.79 Million | 17.55 Million | 17.32 Million |
| Gross Margin | 1.00 | - | - | 0.49 | - | 0.99 |
| EBIT Margin | -13.21 | - | - | - | - | -19.38 |
| Profit Margin | -12.45 | - | - | -30.75 | - | -19.44 |
| EBITDA | -414.49 Million | -378.87 Million | -617.34 Million | - | -402.34 Million | -543.42 Million |
| Earnings Before Tax Margin | -13.21 | - | - | -30.62 | - | -20.52 |
MGX
9405
IVCGF
SHUR
BOL
HTNGF